Top Page
Appili Therapeutics Inc Class A
(OTC:APLI)
Appili Therapeutics Inc Class A (APLI) vs. S&P 500 (SPY)
Appili Therapeutics Inc Class A Business Overview & Revenue Model
Appili Therapeutics Inc Class A Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 124.75K | 827.41K | 334.18K | 1.39M | 0.00 | 199.11K | Gross Profit |
| 114.09K | 827.41K | 327.91K | 1.39M | -14.84K | 199.11K | EBIT |
| -1.92M | -2.16M | -7.91M | -24.68M | -16.30M | -6.13M | EBITDA |
| -1.28M | -2.10M | -8.19M | -24.31M | -14.87M | -5.63M | Net Income Common Stockholders |
| -3.96M | -3.78M | -9.24M | -25.12M | -14.33M | -5.42M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 94.49K | 94.49K | 2.47M | 6.66M | 16.12M | 10.54M | Total Assets |
| 1.49M | 1.49M | 3.13M | 8.28M | 18.32M | 11.17M | Total Debt |
| 8.18M | 8.18M | 7.67M | 4.98M | 1.03M | 1.00M | Net Debt |
| 8.09M | 8.09M | 5.20M | -1.69M | -10.03M | -9.50M | Total Liabilities |
| 12.42M | 12.42M | 10.53M | 11.55M | 5.56M | 2.33M | Stockholders Equity |
| -10.92M | -10.92M | -7.40M | -3.27M | 12.75M | 8.85M |
| Cash Flow | Free Cash Flow | ||||
| -641.51K | -2.49M | -10.10M | -19.08M | -11.46M | -4.26M | Operating Cash Flow |
| -639.15K | -2.46M | -10.10M | -19.08M | -11.45M | -4.26M | Investing Cash Flow |
| -1.71K | -29.06K | -3.17K | 5.06M | -4.99M | -1.14K | Financing Cash Flow |
| 220.56K | 122.05K | 5.91M | 9.56M | 17.02M | 9.36M |
Appili Therapeutics Inc Class A Technical Analysis
Appili Therapeutics Inc Class A Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | C$412.48M | 3.50 | 57.36% | ― | 39.36% | 746.02% | |
68 Neutral | C$49.28M | 29.31 | 5.32% | ― | -4.67% | -60.94% | |
62 Neutral | $176.31M | 13.66 | 31.34% | ― | -3.13% | ― | |
52 Neutral | $5.19B | 3.04 | -44.20% | 2.82% | 16.59% | -0.39% | |
47 Neutral | C$3.64M | ― | 34.61% | ― | -89.15% | 25.91% |
Appili Therapeutics Inc Class A Corporate Events
Appili Therapeutics announced the publication of a manuscript in Frontiers in Bacteriology, highlighting the potential of their biodefense vaccine, ATI-1701, in preventing tularemia outbreaks. The review consolidates recent findings on immune responses to Francisella tularensis, the pathogen causing tularemia, and suggests pathways for effective vaccine development. ATI-1701 is positioned as a potentially valuable vaccine due to the lack of approved vaccines for tularemia in major markets, emphasizing its importance as a biodefense priority globally.
Spark’s Take on TSE:APLI Stock
According to Spark, TipRanks’ AI Analyst, TSE:APLI is a Neutral.
Appili Therapeutics Inc is facing significant financial instability, with declining revenues and negative equity being major concerns. Technical indicators show some stabilization, but bearish momentum and a challenging valuation due to negative earnings dampen the outlook. Positive corporate events, such as new patents and funding applications, offer potential upside, but the overall stock score remains low due to the prevailing financial difficulties.
To see Spark’s full report on TSE:APLI stock, click here.
Appili Therapeutics has announced the granting of new patents by the United States and Mexican patent offices for its oral formulation of metronidazole, LIKMEZ. These patents, which expire in 2039, enhance the protection of LIKMEZ by covering its unique taste-masked composition and therapeutic applications. This development is significant for Appili as it strengthens the company’s market position and supports the commercialization efforts of its partner, Saptalis Pharmaceuticals. The listing of the U.S. patent in the FDA’s Orange Book further solidifies the product’s market presence, with Saptalis planning a re-launch under its own label.
Spark’s Take on TSE:APLI Stock
According to Spark, TipRanks’ AI Analyst, TSE:APLI is a Underperform.
Appili Therapeutics faces significant financial instability with declining revenues and negative cash flows, which negatively impact its overall stock score. However, positive corporate events such as federal funding applications and strategic partnerships offer potential upside. Technical analysis suggests some stabilization, but the valuation remains challenging due to ongoing losses.
To see Spark’s full report on TSE:APLI stock, click here.
Appili Therapeutics announced that its CEO, Don Cilla, will join Aditxt’s CEO for a discussion on emerging infectious diseases and strategic partnerships. The event will highlight Appili’s operational achievements, including $117 million in new federal funding applications, and the ongoing going-private transaction with Aditxt. The discussion will also emphasize Appili’s success in securing non-dilutive funding and its plans to accelerate the development of treatments for infectious diseases.
Appili Therapeutics announced the submission of four new U.S. federal funding proposals totaling $117.5 million, aimed at advancing treatments for infectious diseases. The company also updated its transaction with Aditxt and extended the deadline for its going-private transaction. Appili’s strategic moves, including joining the Medical CBRN Defense Consortium, highlight its commitment to U.S. biodefense and preparedness, positioning it as a key player in developing medical countermeasures.
Appili Therapeutics reported its third-quarter fiscal results, highlighting significant shareholder support for a take-private transaction with Aditxt and progress in its key pipeline programs. The company is advancing ATI-1701, a biodefense vaccine candidate with substantial U.S. government backing, and ATI-1801, a topical antiparasitic product with FDA alignment on development requirements. Additionally, Appili has launched LIKMEZ™, an FDA-approved liquid formulation of metronidazole, in partnership with Saptalis Pharmaceuticals, addressing challenges in oral drug compliance.